Showing 6011-6020 of 9991 results for "".
- LITE: Home-based Narrow Band UVB Phototherapy for Psoriasis Non-Inferior to Office-based Treatmenthttps://practicaldermatology.com/news/lite-home-based-narrow-band-uv-b-phototherapy-for-psoriasis-noninferior-to-office-based-treatment/2462425/Home-based phototherapy for the treatment of psoriasis was non-inferior to office-based therapy, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. Researchers for the Light Treatment Effectiveness (LITE) study, looking at whether home
- FRONTIER-2: Novel Oral Peptide Maintains Safety, Efficacy Out to 1 Yearhttps://practicaldermatology.com/news/frontier-2-novel-il-23-targting-oral-peptide-maintains-safety-efficacy-out-to-1-year/2462424/A targeted oral peptide targeting interleukin-23 (IL-23) was associated with high rates of clearance and consistent safety through 1 year of treatment in adults with moderate-to-severe plaque psoriasis, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in
- After Positive Phase 1 Results, Apogee to Test Twice-Yearly Dosing of Atopic Dermatitis Drug Candidatehttps://practicaldermatology.com/news/after-positive-phase-1-results-apogee-to-test-twice-yearly-dosing-of-atopic-dermatitis-drug-candidate/2462261/Apogee Therapeutics announced positive interim phase 1 data from its first-in-human study of APG777, one of its lead product candidates being developed as a frontline treatment for moderate-to-severe atopic dermatitis (AD) and other inflammatory diseases. Pharmacokinetic (PK) data showed a half-l
- Dermavant to Present New ADORING Data from Phase 3 Trials of Vtama Cream for AD at 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/dermavant-to-present-new-adoring-data-from-phase-3-trials-of-vtama-cream-for-ad-at-2024-aad-annual-meeting/2462258/Dermavant Sciences announced that new ADORING data, including treatment of patients with skin of color, from phase 3 trials of Vtama (tapinarof) cream 1% in adults and children 2 years of age and older with atopic dermatitis (AD), will be presented at the 2024 American Academy of Dermatology annu
- Long-term Outcomes Impaired by Cutaneous Chronic Graft-vs-Host Diseasehttps://practicaldermatology.com/news/improved-melanoma-prognosis-with-31-gep/2462255/New analysis results indicate that cutaneous chronic graft-vs-host disease (GVHD) was linked with impaired long-term patient-reported outcomes (PROs). Researchers for the 9-center study conducted by the Chronic GVHD Consortium examined the association between different ty
- Study Highlights Fatigue Experienced by Psoriasis Patientshttps://practicaldermatology.com/news/study-highlights-fatigue-experienced-in-psoriasis/2462247/A new analysis in the Journal of the American Academy of Dermatology sought to tease out drivers of fatigue in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Researchers for the study examined various factors contributing to fatigue in these individuals using
- Galderma Announces Filing Acceptance for Investigational Prurigo Nodularis and AD Treatmenthttps://practicaldermatology.com/news/galderma-announces-filing-recepetion-for-investigational-prurigo-nodularis-treatment/2462243/Galderma announced the acceptance of its Biologics License Applications for nemolizumab, a first-in-class monoclonal antibody IL-31 inhibitor, for the treatment of prurigo nodularis in adults and adolescents with moderate-to-severe atopic dermatitis (AD). The agency, according to a news
- Six Dermatology Biotechs Combine to Form Alys Pharmaceuticalshttps://practicaldermatology.com/news/six-dermatology-biotechs-combine-to-form-alys-pharmaceuticals/2462241/Originating from the aggregation of six asset-centric dermatology companies, Alys Pharmaceuticals was launched with $100 million financing by Medicxi, a healthcare-focused investment firm. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharma
- Cutera Announces International Commercial Launch of AviClear for the Treatment of Acnehttps://practicaldermatology.com/news/cutera-announces-international-commercial-launch-of-aviclear-for-the-treatment-of-acne/2462240/Cutera announced the international limited commercial release of AviClear, which the company describes as the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. AviClear is now commercially available, on a limited basis, in the UK, Europe, a
- Federated Learning Comparable to Traditional Learning Methods for AI-based Melanoma Diagnosishttps://practicaldermatology.com/news/federated-learning-comparable-to-traditional-learning-methods-for-ai-based-melanoma-diagnosis/2462238/A decentralized federated learning approach was comparable in diagnostic performance to traditional centralized and ensemble learning methods in AI-based melanoma diagnosis, new research suggests. Study authors conducted a multicentric, single-arm diagnostic study conducted across six Ger